Evidence map›Paper›PMID 25867094›Full record

ArticleEuropean journal of immunology2015

Pemphigus is associated with KIR3DL2 expression levels and provides evidence that KIR3DL2 may bind HLA-A3 and A11 in vivo.

Danillo G Augusto, Geraldine M O'Connor, Sara C Lobo-Alves, Sara Bass, Maureen P Martin, Mary Carrington, Daniel W McVicar, Maria Luiza Petzl-Erler

Open access · bronzeAbstract read
In one paragraph

Article in European journal of immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Current research status of HLA in immune-related diseases.Immunity, inflammation and disease · 2021
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Can we make a better match or mismatch with KIR genotyping?Hematology. American Society of Hematology. Education Program · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Danillo G AugustoDepartamento de Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Geraldine M O'ConnorCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Sara C Lobo-AlvesDepartamento de Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Sara BassLeidos Biomedical Research, Cancer and Inflammation Program, Laboratory for Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Maureen P MartinLeidos Biomedical Research, Cancer and Inflammation Program, Laboratory for Experimental Immunology, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Boston, MA, USA.
Daniel W McVicarCancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA.
Maria Luiza Petzl-ErlerDepartamento de Genética, Universidade Federal do Paraná, Curitiba, PR, Brazil.
Leidos (United States) · USNational Cancer Institute · USUniversidade Federal do Paraná · BRRagon Institute of MGH, MIT and Harvard · US

Funding

Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
Molecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8M
Charaterization of the Expression and Ligands of KIR3DS1ZIABC010747 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCVICAR, DANIEL W. · 2009 to 2018
$1.8M
Charaterization of the Expression and Ligands of KIR3DS1Z01BC010747 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCVICAR, DANIEL W. · 2006 to 2008
$346k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC010747NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Although HLA-A3 and A11 have been reported to be ligands for KIR3DL2, evidence for any in vivo relevance of this interaction is still missing. To explore the functional importance of KIR3DL2 allelic variation, we analyzed the autoimmune disease pemphigus foliaceus, previously associated (lower risk) with activating KIR genes. KIR3DL2*001 was increased in patients (odds ratio (OR) = 2.04; p = 0.007). The risk was higher for the presence of both KIR3DL2*001 and HLA-A3 or A11 (OR = 3.76, p = 0.013), providing the first evidence that HLA-A3 and A11 may interact with KIR3DL2 in vivo. The nonsynonymous single nucleotide polymorphism 1190T (rs3745902) was associated with protection (OR = 0.52, p = 0.018). This SNP results in a threonine-to-methionine substitution. Individuals who have methionine in this position exhibit a lower percentage of KIR3DL2-positive natural killer (NK) cells and also lower intensity of KIR3DL2 on expressing natural killer cells; additionally, we show that the expression of KIR3DL2 is independent of other killer cell immunoglobulin-like receptors. Pemphigus foliaceus is a very unique complex disease strongly associated with immune-related genes. It is the only autoimmune disease known to be endemic, showing a strong correlation with environmental factors. Our data demonstrate that this relatively unknown autoimmune disease may facilitate understanding of the molecular mechanisms of KIR3DL2 ligand recognition.

Indexed as

Flow CytometryGenetic Predisposition to DiseaseGenotypeHLA-A11 AntigenHLA-A3 AntigenHumansPemphigusPolymorphism, Single NucleotideProtein BindingReceptors, KIR3DL2HLA-A11 AntigenHLA-A3 AntigenKIR3DL2 protein, humanReceptors, KIR3DL2Allele polymorphismAutoimmunityHLAKIRNK cellsPemphigus foliaceus

Identifiers

PMID25867094
PMCPMC4530613
OpenAlexW2044717587

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.